PURPOSE: The goal of the present paper was to encapsulate oligonucleotides in a new particulate carrier in order to protect them from enzymatic degradation. METHODS: Nanocapsules with an aqueous core containing oligonucleotides were prepared by interfacial polymerization of isobutylcyanoacrylate in a W/O emulsion. Ultracentrifugation and re-suspension in water yielded a dispersion of these containing an aqueous core nanocapsules. Zeta potential measurements and quenching of fluorescence of fluorescein-bounded oligonucleotides were used to study the localization of the oligonucleotides. Oligonucleotide degradation studies were carried out in fetal calf serum. RESULTS: Polydisperse nanocapsules of size ranging from 20 to 400 nm were obtained. Oligonucleotide loading did not significantly influence the zeta potential, suggesting they were located within the core of the nanocapsules. Fluorescence quenching assays confirmed this localization. When encapsulated in the nanocapsules and incubated in the presence of serum, the oligonucleotides were efficiently protected from degradation by nucleases, whereas oligonucleotides adsorbed onto nanospheres were protected less efficiently. CONCLUSIONS: This paper describes, for the first time, a nanotechnology able to encapsulate oligonucleotides rather than adsorbing them at the surface of a solid support. Such a formulation has great potential for oligonucleotide delivery.
PURPOSE: The goal of the present paper was to encapsulate oligonucleotides in a new particulate carrier in order to protect them from enzymatic degradation. METHODS: Nanocapsules with an aqueous core containing oligonucleotides were prepared by interfacial polymerization of isobutylcyanoacrylate in a W/O emulsion. Ultracentrifugation and re-suspension in water yielded a dispersion of these containing an aqueous core nanocapsules. Zeta potential measurements and quenching of fluorescence of fluorescein-bounded oligonucleotides were used to study the localization of the oligonucleotides. Oligonucleotide degradation studies were carried out in fetal calf serum. RESULTS: Polydisperse nanocapsules of size ranging from 20 to 400 nm were obtained. Oligonucleotide loading did not significantly influence the zeta potential, suggesting they were located within the core of the nanocapsules. Fluorescence quenching assays confirmed this localization. When encapsulated in the nanocapsules and incubated in the presence of serum, the oligonucleotides were efficiently protected from degradation by nucleases, whereas oligonucleotides adsorbed onto nanospheres were protected less efficiently. CONCLUSIONS: This paper describes, for the first time, a nanotechnology able to encapsulate oligonucleotides rather than adsorbing them at the surface of a solid support. Such a formulation has great potential for oligonucleotide delivery.
Authors: N Dean; R McKay; L Miraglia; R Howard; S Cooper; J Giddings; P Nicklin; L Meister; R Ziel; T Geiger; M Muller; D Fabbro Journal: Cancer Res Date: 1996-08-01 Impact factor: 12.701
Authors: V Lenaerts; P Couvreur; D Christiaens-Leyh; E Joiris; M Roland; B Rollman; P Speiser Journal: Biomaterials Date: 1984-03 Impact factor: 12.479
Authors: Nedjma Toub; Jean-Rémi Bertrand; Ali Tamaddon; Hind Elhamess; Hervé Hillaireau; Andrei Maksimenko; Jean Maccario; Claude Malvy; Elias Fattal; Patrick Couvreur Journal: Pharm Res Date: 2006-05-02 Impact factor: 4.200
Authors: Andrei Maksimenko; Claude Malvy; Gregory Lambert; Jean-Rémy Bertrand; Elias Fattal; Jean Maccario; Patrick Couvreur Journal: Pharm Res Date: 2003-10 Impact factor: 4.200